{"id":"https://openalex.org/W2115753233","doi":"https://doi.org/10.1093/annonc/mdt155","title":"Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors","display_name":"Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors","publication_year":2013,"publication_date":"2013-05-09","ids":{"openalex":"https://openalex.org/W2115753233","doi":"https://doi.org/10.1093/annonc/mdt155","mag":"2115753233","pmid":"https://pubmed.ncbi.nlm.nih.gov/23658373"},"language":"en","primary_location":{"id":"doi:10.1093/annonc/mdt155","doi":"https://doi.org/10.1093/annonc/mdt155","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdt155","pdf_url":"http://www.annalsofoncology.org/article/S0923753419368218/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.annalsofoncology.org/article/S0923753419368218/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052504518","display_name":"Toni K. Choueiri","orcid":"https://orcid.org/0000-0002-9201-3217","observed_orcids":["https://orcid.org/0000-0002-9201-3217"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"T.K. Choueiri","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","Department of Medical Oncology, Dana-Farber Cancer Institute,Boston,USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute,Boston,USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018055906","display_name":"Youjin Je","orcid":"https://orcid.org/0000-0002-2099-4204","observed_orcids":["https://orcid.org/0000-0002-2099-4204","https://orcid.org/0000-0001-8714-2690"]},"institutions":[{"id":"https://openalex.org/I35928602","display_name":"Kyung Hee University","ror":"https://ror.org/01zqcg218","country_code":"KR","type":"education","lineage":["https://openalex.org/I35928602"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Y. Je","raw_affiliation_strings":["Department of Food and Nutrition, Kyung Hee University, Seoul, Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Food and Nutrition, Kyung Hee University, Seoul, Korea","institution_ids":["https://openalex.org/I35928602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052069729","display_name":"Guru Sonpavde","orcid":"https://orcid.org/0000-0002-1010-9611","observed_orcids":["https://orcid.org/0000-0002-1010-9611"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Sonpavde","raw_affiliation_strings":["Department of Medical Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":null,"display_name":"C.J. Richards","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C.J. Richards","raw_affiliation_strings":["Department of Medicine, Beth Israel Deaconess Medical Center, Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Beth Israel Deaconess Medical Center, Boston","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018275141","display_name":"Matthew D. Galsky","orcid":"https://orcid.org/0000-0001-7655-9378","observed_orcids":["https://orcid.org/0000-0001-7655-9378"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.D. Galsky","raw_affiliation_strings":["Department of Medical Oncology, Mount Sinai School of Medicine, Tisch Cancer Institute, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Mount Sinai School of Medicine, Tisch Cancer Institute, New York","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015096941","display_name":"Paul Linh Nguyen","orcid":"https://orcid.org/0000-0003-4268-3973","observed_orcids":["https://orcid.org/0000-0003-4268-3973"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P.L. Nguyen","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","Department of Radiation Oncology, Brigham and Women's Hospital, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Radiation Oncology, Brigham and Women's Hospital, Boston, USA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113600233","display_name":"Fabio A. Schutz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162743","display_name":"Hospital S\u00e3o Paulo","ror":"https://ror.org/050z9fj14","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I4210162743"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"F. Schutz","raw_affiliation_strings":["Department of Medical Oncology, Hospital Sao Paulo, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Hospital Sao Paulo, Brazil","institution_ids":["https://openalex.org/I4210162743"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114232502","display_name":"Daniel Y.C. Heng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168635309","display_name":"University of Calgary","ror":"https://ror.org/03yjb2x39","country_code":"CA","type":"education","lineage":["https://openalex.org/I168635309"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"D.Y. Heng","raw_affiliation_strings":["Department of Medical Oncology, University of Calgary, Calgary, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, University of Calgary, Calgary, Canada","institution_ids":["https://openalex.org/I168635309"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019688174","display_name":"Marina Dusevic Kaymakcalan","orcid":"https://orcid.org/0000-0003-4956-9129","observed_orcids":["https://orcid.org/0000-0003-4956-9129"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M.D. Kaymakcalan","raw_affiliation_strings":["Department of Pharmacy, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5052504518"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":0.5325,"has_fulltext":true,"cited_by_count":35,"citation_normalized_percentile":{"value":0.45776752,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"24","issue":"8","first_page":"2092","last_page":"2097"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.006099999882280827,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9639999866485596},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9629999995231628},{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":1.0},{"id":"https://openalex.org/keywords/fatal-adverse-events","display_name":"fatal adverse events","score":0.9319999814033508},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.9610000252723694},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9729999899864197},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.39500001072883606}],"concepts":[{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.9712101221084595},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.9436904191970825},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9120209217071533},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5854613184928894},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5742816925048828},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5487884879112244},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5419841408729553},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5398241281509399},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.5079720616340637},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4875490069389343},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4804358184337616},{"id":"https://openalex.org/C2777921159","wikidata":"https://www.wikidata.org/wiki/Q32089","display_name":"Sirolimus","level":2,"score":0.46274426579475403},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.4591050148010254},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42719414830207825},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4217643737792969},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.41198110580444336},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35218939185142517},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.1728082299232483},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068338","descriptor_name":"Everolimus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1093/annonc/mdt155","doi":"https://doi.org/10.1093/annonc/mdt155","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdt155","pdf_url":"http://www.annalsofoncology.org/article/S0923753419368218/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},{"id":"pmid:23658373","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23658373","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of oncology : official journal of the European Society for Medical Oncology","raw_type":"Journal Article"},{"id":"pmh:oai:open-archive.highwire.org:annonc:mdt155v1","doi":null,"is_oa":false,"landing_page_url":"http://annonc.oxfordjournals.org/cgi/content/short/mdt155v1","pdf_url":null,"source":{"id":"https://openalex.org/S4406923041","display_name":"HighWire Press Open Archive","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"TEXT"}],"best_oa_location":{"id":"doi:10.1093/annonc/mdt155","doi":"https://doi.org/10.1093/annonc/mdt155","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdt155","pdf_url":"http://www.annalsofoncology.org/article/S0923753419368218/pdf","source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2115753233.pdf","grobid_xml":"https://content.openalex.org/works/W2115753233.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W1964435302","https://openalex.org/W1972787599","https://openalex.org/W1977309860","https://openalex.org/W1985934694","https://openalex.org/W1986215651","https://openalex.org/W2009937603","https://openalex.org/W2020773732","https://openalex.org/W2024586523","https://openalex.org/W2035495486","https://openalex.org/W2057692942","https://openalex.org/W2075024589","https://openalex.org/W2077900583","https://openalex.org/W2083378657","https://openalex.org/W2104241646","https://openalex.org/W2111743784","https://openalex.org/W2115686439","https://openalex.org/W2118677643","https://openalex.org/W2125435699","https://openalex.org/W2127063807","https://openalex.org/W2135387190","https://openalex.org/W2138129102","https://openalex.org/W2147394591","https://openalex.org/W2148933046","https://openalex.org/W2153061474","https://openalex.org/W2153867442","https://openalex.org/W2157823046","https://openalex.org/W2164977235","https://openalex.org/W2167123965","https://openalex.org/W2167188058","https://openalex.org/W2198308217","https://openalex.org/W2327241693","https://openalex.org/W2468996569","https://openalex.org/W2587781858","https://openalex.org/W2991792334"],"related_works":["https://openalex.org/W2027706632","https://openalex.org/W2589385999","https://openalex.org/W2139524403","https://openalex.org/W2114961850","https://openalex.org/W3011583190","https://openalex.org/W2002140390","https://openalex.org/W2908097512","https://openalex.org/W4212978261","https://openalex.org/W2589808873","https://openalex.org/W2207024576"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}